Adjuvants for vaccines;Adjuvanzien für impfstoffe

Medizinische Monatsschrift fur Pharmazeuten

Volumn 25, Issue 11, 2002, Pages 373-378

  Bröker, Michael ^a  

^a Chiron Behring GmbH & Co   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ALUMINUM HYDROXIDE; ALUMINUM PHOSPHATE; BACTERIAL POLYSACCHARIDE; CALCIUM PHOSPHATE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA VACCINE; GLYCOPROTEIN; HEPATITIS B ANTIGEN; INACTIVATED VACCINE; INFLUENZA VACCINE; INORGANIC COMPOUND; ISCOM; LACTIC ACID; LIPOSOME; LYSOZYME; MALONIC ACID; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; OVALBUMIN; TETANUS TOXOID; VACCINE; VIROSOME;

ADSORPTION; BIOCOMPATIBILITY; DESORPTION; DRUG FORMULATION; EMULSION; SHORT SURVEY;

ADJUVANTS, IMMUNOLOGIC; HUMANS; VACCINES;

EID: 0036848369     PISSN: 03429601     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (13)

1. Jefferson T. A basic glossary of vaccinology. J Epidemiol Comm Health 2001;55:294-5.
2. Vogel FR, Powell MF. A compendium of vaccine adjuvants and excipients. In: Powell MF, Newman MJ, editors. Vaccine Design: The Subunit and Adjuvant Approach. New York: Plenum Press, 1995:141-228.
3. Gupta RK, Rost BE, Relyveld E, Siber GR. Adjuvant properties of aluminium and calcium compound. In: Powell MF. Newman MJ, editors. Vaccine Design: The Subunit and Adjuvant Approach. New York: Plenum Press, 1995:229-48.
4. Hem SL, White JL. Structure and properties of aluminium-containing adjuvants. In: Powell MF. Newman MJ, editors. Vaccine Design: The Subunit and Adjuvant Approach. New York: Plenum Press. 1995:249-76.
5. Shi Y, Hogen-Esch H, Hem SL. Change in the degree of adsorption of proteins by aluminium-containing adjuvants following exposure to interstitial fluid: Freshly prepared and aged model vaccines. Vaccine 2002;20:80-5.
6. Lehmann HG. Influenza-virus-spaltvakzine: mit oder ohne adjuvans? Die Gelben Hefte 1981;21:76-80.
7. Ott G, Barchfield GL, Chernoff D, Radhakrishnan R. MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. In: Powell MF, Newman MJ, editors. Vaccine Design: The Subunit and Adjuvant Approach. New York: Plenum Press, 1995:277-96.
8. Ott G, Radhakrishnan R, Fang JH, Hora M. The adjuvant MF59: A 10-year perspective. In: O'Hagan DT, editor. Methods in Molecular Medicine. Vaccine Adjuvants: Preparation Methods and Research Protocols. Totowa, New York: Humana Press. 2000;42:211-28.
9. De Donato S, Granoff D, Minutello M, Lecchi G, et al. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine 1999;17:3094-101.
10. Gasparini R, Pozzi T, Montomoli E, Fragapane E. et al. Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects. Eur J Epidemiol 2001;17:135-40.
11. Minutello M, Senatore F, Ceccinelli G, Bianchi M. et al. Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine 1999;17:99-104.
12. Schweiger B, Harder H, Seiler V, Beinert T. Erste erfahrungen mit einem adjuvierten influenzaimpfstoff bei onkologischen patienten. ImpfDialog 2001;1:86-90.
13. Nicholson KG, Colegate AE, Podda A, Stephenson I, et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: A randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001;357:1937-43.